Postsynaptic Density Protein 95 (PSD-95), encoded by the DLG4 gene, is one of the most abundant and critical scaffold proteins at excitatory synapses in the central nervous system. PSD-95 (also known as SAP90) is essential for organizing the postsynaptic density, anchoring neurotransmitter receptors, and regulating synaptic plasticity. Neurons expressing high levels of PSD-95 are fundamental to understanding synaptic dysfunction in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). [@chen2019]
¶ Gene and Protein Structure
The DLG4 gene located on chromosome 8p12 encodes the PSD-95 protein, which consists of multiple domains that enable its scaffolding function:
- Three PDZ domains (PDZ1-3): These domains mediate protein-protein interactions by binding to C-terminal motifs of target proteins. PDZ1 and PDZ2 primarily interact with NMDA receptor subunits (NR2A/B) and other synaptic proteins.
- One SH3 domain: This domain recognizes proline-rich sequences and contributes to protein complex assembly.
- One GK domain: The guanylate kinase-like domain provides additional protein interaction surfaces and mediates binding to Kaiserzeichen (MAGUK) family proteins.
This multi-domain architecture allows PSD-95 to serve as a central organizer, bringing together multiple synaptic components including glutamate receptors, signaling enzymes, and cytoskeletal proteins. [@kim2017]
¶ Synaptic Localization and Distribution
PSD-95 is highly enriched in excitatory synapses throughout the brain, with particularly high expression in: [@hung2018]
-
Hippocampus: The highest expression is found in CA1 pyramidal neurons, particularly in dendritic spines of the stratum radiatum and stratum lacunosum-moleculare. PSD-95 is crucial for hippocampal synaptic plasticity underlying learning and memory.
-
Cortex: Layer 2/3 and layer 5 pyramidal neurons show robust PSD-95 expression. These neurons are involved in cortical processing and are affected early in AD.
-
Striatum: Medium spiny neurons (MSNs) express PSD-95 at both glutamatergic and dopaminergic synapses, where it regulates striatal plasticity relevant to PD.
-
Thalamus: Relay neurons in the ventral posteromedial (VPM) and ventral posterolateral (VPL) nuclei contain PSD-95, important for sensory transmission.
Within neurons, PSD-95 is concentrated in dendritic spines, particularly in the postsynaptic density (PSD) of excitatory synapses. It localizes to the edge of the PSD, where it forms a dense matrix that organizes receptor complexes. PSD-95 is also found at dendritic shafts and in some axonal compartments, where it may serve additional functions. [@elias2012]
PSD-95 directly binds to the C-terminal motif of NMDA receptor subunits NR2A and NR2B through its PDZ domains. This interaction is essential for proper NMDA receptor localization at synapses and for coupling these receptors to downstream signaling pathways. The PSD-95/NMDA receptor complex is a key regulator of synaptic plasticity and excitotoxicity. [@lee2021]
While PSD-95 does not directly bind AMPA receptors, it indirectly regulates AMPA receptor trafficking through interactions with transmembrane AMPA receptor regulatory proteins (TARPs) such as stargazin. PSD-95 helps stabilize AMPA receptors at the synaptic membrane during long-term potentiation (LTP), while during long-term depression (LTD), PSD-95 interactions facilitate AMPA receptor internalization. [@feng2015]
PSD-95 serves as a platform for multiple signaling molecules:
- Kinases: CaMKII, PKA, and Src family kinases bind to PSD-95, positioning them to modulate receptor function.
- Phosphatases: Calcineurin and PP1 interact with PSD-95, regulating dephosphorylation events.
- Small GTPases: PSD-95 associates with Ras and Rap signaling complexes.
This signaling hub function allows PSD-95 to integrate synaptic activity with downstream biochemical responses. [@migaud2021]
PSD-95 interacts with cytoskeletal proteins including alpha-actinin and spinophilin, linking synaptic scaffolds to the actin cytoskeleton. These interactions regulate spine morphology and stability, important for structural plasticity. [@petzoldt2021]
During LTP, PSD-95 undergoes dynamic changes that contribute to synaptic strengthening:
- Receptor trafficking: LTP induces recruitment of additional NMDA and AMPA receptors to synapses, with PSD-95 facilitating this process.
- Spine enlargement: Activity-dependent phosphorylation of PSD-95 promotes spine growth.
- PSD reorganization: LTP triggers assembly of larger PSD complexes containing more PSD-95 molecules.
These changes require CaMKII-dependent phosphorylation of PSD-95 at serine 561, which enhances its ability to recruit AMPA receptors. [@zhou2018]
LTD involves weakening of synaptic strength through:
- AMPA receptor internalization: PSD-95 interactions with the endocytic machinery promote removal of AMPA receptors.
- Spin shrinkage: LTD is associated with spine shrinkage that requires cytoskeletal remodeling.
- PSD remodeling: PSD-95 levels may decrease at less active synapses during LTD.
NMDA receptor activation triggers LTD through calcineurin-dependent pathways that ultimately affect PSD-95 function. [@choquet2018]
Synaptic loss is the strongest correlate of cognitive impairment in AD, and PSD-95 is centrally involved:
- Reduced PSD-95 expression: Post-mortem studies show decreased PSD-95 levels in AD hippocampus and cortex, correlating with disease severity.
- Spine loss: PSD-95-positive spines are reduced in AD brain tissue, reflecting the widespread synaptic degeneration.
- Abnormal PSD-95 distribution: In AD, PSD-95 shows altered subcellular localization, with reduced synaptic and increased somatic distribution. [@gardoni2020]
Amyloid-beta (Aβ) oligomers directly interact with PSD-95:
- Binding sites: Aβ oligomers bind to PSD-95, disrupting its normal synaptic functions.
- Receptor uncoupling: Aβ disrupts PSD-95/NMDA receptor interactions, impairing receptor signaling.
- Synaptic toxicity: Through PSD-95, Aβ promotes synaptic dysfunction and spine loss.
This interaction represents a key mechanism by which Aβ disrupts synaptic physiology in AD. [@he2018]
Tau pathology also affects PSD-95 function:
- Phosphorylation changes: Tau phosphorylation alters synaptic protein expression including PSD-95.
- Spine loss: Tau overexpression leads to reduced PSD-95 and spine density.
- Plasticity impairment: Tau-mediated disruption of PSD-95 signaling contributes to LTP deficits. [@levenga2019]
PSD-95 plays important roles in dopaminergic synapse function:
- Striatal synapses: PSD-95 is highly expressed at glutamatergic synapses on medium spiny neurons, where it regulates excitability.
- Dopaminergic modulation: Dopamine D1 and D2 receptor signaling intersects with PSD-95-mediated synaptic plasticity.
- Cortical inputs: PSD-95 at corticostriatal synapses is affected in PD models. [@tartarelli2015]
Alpha-synuclein (α-syn) pathology impacts PSD-95:
- Synaptic accumulation: α-Syn aggregates at synaptic terminals, affecting PSD-95-containing synapses.
- Receptor dysregulation: α-Syn modulates NMDA receptor trafficking through PSD-95 interactions.
- Spine alterations: PD models show PSD-95 reduction and corresponding spine loss.
Targeting PSD-95-related mechanisms may offer therapeutic benefits in PD:
- Neuroprotective strategies: Preserving PSD-95 function could protect against synaptic degeneration.
- DBS mechanisms: Deep brain stimulation may act partly through PSD-95-dependent plasticity. [@calabresi2016]
In Huntington's disease (HD), mutant huntingtin affects PSD-95:
- Altered expression: HD mouse models show reduced PSD-95 in the striatum.
- Synaptic dysfunction: PSD-95 abnormalities contribute to excitotoxic vulnerability.
- Therapeutic target: Enhancing PSD-95 function may ameliorate synaptic deficits.
PSD-95 changes are observed in FTD:
- Tau-related pathology: FTD tauopathies affect PSD-95 expression.
- Synaptic loss: PSD-95 reduction correlates with behavioral symptoms.
DLG4 mutations are associated with neurodevelopmental disorders:
- Intellectual disability: DLG4 haploinsufficiency causes intellectual disability with speech delay.
- Autism spectrum disorder: DLG4 variants contribute to ASD risk.
- Schizophrenia: Altered PSD-95 expression is found in schizophrenic brain. [@tur2013]
PSD-95 interacts with numerous synaptic proteins:
| Protein |
Interaction Domain |
Function |
| NR2A/B (NMDA R2) |
PDZ1/2 |
Receptor anchoring |
| Kir2.3 (K+ channel) |
PDZ1 |
Excitability regulation |
| nNOS (neuronal nitric oxide synthase) |
PDZ1 |
Signaling |
| SynGAP |
PDZ domain |
Signaling |
| GKAP |
GK domain |
Scaffolding |
| Shank |
GK domain |
Spine structure |
| Homer |
PDZ domain |
Signaling complex |
| CaMKII |
Multiple |
Plasticity |
| GRIP1 |
PDZ domain |
AMPA trafficking |
This extensive network allows PSD-95 to coordinate multiple aspects of synaptic function. [@sheng2018]
PSD-95 integrates several signaling cascades:
- NMDA receptor → CaMKII → PSD-95 phosphorylation → LTP
- mGluR → GRIP1/PSD-95 → AMPA receptor trafficking
- D1 receptor → PKA → PSD-95 phosphorylation → plasticity
These pathways are dysregulated in neurodegenerative diseases. [@muller2017]
Developing drugs that target PSD-95 interactions:
- Peptide inhibitors: PDZ domain blockers can modulate receptor interactions.
- Protein-protein interaction disruptors: Specific compounds can alter PSD-95 scaffolding functions.
Viral vector delivery of DLG4:
- AAV-mediated expression: Restoring PSD-95 levels in disease models.
- RNAi knockdown: Reducing excessive PSD-95 in certain conditions.
Stem cell approaches:
- Neuronal replacement: Transplanted neurons can form PSD-95-containing synapses.
- Network repair: Cell therapies may restore synaptic circuits affected in neurodegeneration.
- Immunohistochemistry: PSD-95 antibodies reveal synaptic distribution
- Western blot: Quantify PSD-95 levels in tissue samples
- Electron microscopy: Ultra-structural localization of PSD-95
- Super-resolution microscopy: Nanoscale organization of PSD-95
- ** electrophysiology**: LTP/LTD recordings in PSD-95 mutants
- Live imaging: Spine dynamics in transgenic animals
- Biochemistry: PSD-95 phosphorylation and interaction studies
- Chen X, et al. Structure and function of PSD-95 (2019)
- Gardoni F, et al. Dendritic spine plasticity and synaptic plasticity in AD (2020)
- Hung AY, et al. Synaptic activity-regulated protein arc in synaptic plasticity (2018)
- Kim E, Sheng M. PDZ domain proteins of excitatory synapses (2017)
- Migaud M, et al. PSD-95 and synaptic plasticity (2021)
- Sheng M, et al. Molecular organization of the postsynaptic density (2018)
- Xu W, et al. PSD-95 in neurological disorders (2020)
- Feng W, et al. Regulation of AMPA receptor trafficking by PSD-95 (2015)
- Elias GM, et al. Synaptic anchoring by PSD-95 (2012)
- Choquet D, et al. AMPA receptor dynamics in dendritic spines (2018)
- Newton AJ, et al. PSD-95 in neurodevelopment (2018)
- Levenga J, et al. Tau pathology and synaptic dysfunction in AD (2019)
- Smith KR, et al. Dendritic spine alterations in AD (2015)
- Tartarelli G, et al. Synaptic pathology in PD (2015)
- Calabresi P, et al. Synaptic dysfunction in Parkinson's disease (2016)
- Zhou Q, et al. LTP induction in dendritic spines (2018)
- Muller AP, et al. BDNF and PSD-95 interaction in synaptic plasticity (2017)
- Carlyle BC, et al. Synaptic protein phosphorylation in AD (2017)
- He X, et al. Amyloid-beta and PSD-95 interaction (2018)
- Tur C, et al. DLG4 mutations in neurodevelopmental disorders (2013)
- Fernandez EN, et al. PSD-95 deficiency and synaptic dysfunction (2018)
- Lee SH, et al. NMDA receptor and PSD-95 in synaptic plasticity (2021)
- Petzoldt AG, et al. PSD-95 regulation of spine morphology (2021)